John Tsai

Chief Medical Officer at Novartis AG

John Tsai

John Tsai

Chief Medical Officer at Novartis AG

Overview
RelSci Relationships

2974

Number of Boards

3

Birthday

1967

Age

53

Relationships
RelSci Relationships are individuals John Tsai likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Novartis AG

Relationship likelihood: Strong

Chief Financial Officer at Novartis AG

Relationship likelihood: Strong

Chief Digital Officer at Novartis AG

Relationship likelihood: Strong

General Manager Region Europe Oncology at Novartis Venture Fund

Relationship likelihood: Strong

Former Chief Operating Officer at Novartis Corporation

Relationship likelihood: Strong

President at Novartis Institutes for BioMedical Research, Inc.

Relationship likelihood: Strong

Group General Counsel of Novartis at Novartis AG

Relationship likelihood: Strong

Head of Strategic Venture Capital Fund, Pharma Equities at Novartis AG

Relationship likelihood: Strong

Head of Novartis Business Services (Nbs) at Novartis AG

Relationship likelihood: Strong

Global Head of Novartis Technical Operations (Nto) at Novartis AG

Relationship likelihood: Strong

Paths to John Tsai
Potential Connections via
Relationship Science
You
John Tsai
Chief Medical Officer at Novartis AG
Education

The mission of Washington University in St. Louis is the promotion of learning — learning by students and by faculty. Teaching, the transmission of knowledge, is central to our mission, as is research, the creation of new knowledge. Faculty — composed of scholars, scientists, artists and members of the learned professions — serve society by teaching; by adding to the store of human art, creativity, understanding, and wisdom; and by providing direct services, such as health care. The university offers more than 90 programs and almost 1,500 courses leading to bachelor's, master's and doctoral degrees in a broad spectrum of traditional and interdisciplinary fields, with additional opportunities for minor concentrations and individualized programs.

Career History
Chief Medical Officer
2018 - Current

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Chief Medical Officer & Senior Vice President-Global Medical
2017 - 2018

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Head-Clinical Development
2006 - 2017

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Public Holdings
Restricted data only for RelSci Professional users.
Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by John Tsai. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of John Tsai's profile does not indicate a business or promotional relationship of any kind between RelSci and John Tsai.